Key Takeaways
- • OrbiMed has raised $3 billion in commitments across two new private equity funds targeting healthcare investment in the United States, Europe and Asia, according to the primary article.
- • OrbiMed Private Investments X raised more than $1.9 billion for life sciences venture capital in the U.S. and Europe.
- • OrbiMed Asia Partners VI raised more than $1 billion for healthcare growth equity and venture capital across Asian markets.
- • The firm, with more than $21 billion in assets under management, cited AI, new therapeutic modalities and China's biotechnology growth as drivers of its strategy.
- • Investors include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices; the firm did not disclose individual commitments or a deployment schedule.
Summary
OrbiMed, a global healthcare investment firm with more than $21 billion in assets under management, has raised $3 billion in commitments across two new private equity funds, according to the firm's announcement as reported by citybiz. The raise comprises more than $1.9 billion for OrbiMed Private Investments X, which will focus on venture-stage life sciences businesses in the U.S. and Europe, and more than $1 billion for OrbiMed Asia Partners VI, which will pursue healthcare growth equity and venture capital opportunities across Asian markets.
The two vehicles are designed to finance healthcare companies at different stages of development. Investment strategies span biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services. The Western fund targets companies developing new therapeutics, medical technologies and diagnostic products that often require substantial capital for research, clinical development and commercialization. The Asia fund combines venture and growth investing, allowing the firm to back emerging companies as well as established businesses seeking expansion capital.
Managing partner Carl Gordon said there has never been a more exciting time to invest in life sciences innovation, citing AI, a proliferation of new therapeutic modalities and China's emergence as a biotechnology powerhouse. Carter Neild, also a managing partner, thanked long-standing investors. The firm is led by 20 partners, employs more than 150 professionals and operates 12 locations, including New York, London, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya.
Investors in the funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. OrbiMed did not disclose individual investor commitments, specific portfolio companies or a deployment schedule for either fund. The firm operates through private equity, public equity, and royalty and credit strategies.
The raise adds long-term institutional capital to OrbiMed's platform for healthcare companies that may need multiple financing rounds before reaching commercial scale.
The two vehicles are designed to finance healthcare companies at different stages of development. Investment strategies span biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services. The Western fund targets companies developing new therapeutics, medical technologies and diagnostic products that often require substantial capital for research, clinical development and commercialization. The Asia fund combines venture and growth investing, allowing the firm to back emerging companies as well as established businesses seeking expansion capital.
Managing partner Carl Gordon said there has never been a more exciting time to invest in life sciences innovation, citing AI, a proliferation of new therapeutic modalities and China's emergence as a biotechnology powerhouse. Carter Neild, also a managing partner, thanked long-standing investors. The firm is led by 20 partners, employs more than 150 professionals and operates 12 locations, including New York, London, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya.
Investors in the funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. OrbiMed did not disclose individual investor commitments, specific portfolio companies or a deployment schedule for either fund. The firm operates through private equity, public equity, and royalty and credit strategies.
The raise adds long-term institutional capital to OrbiMed's platform for healthcare companies that may need multiple financing rounds before reaching commercial scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.